Smooth Muscle Cell–targeted RNA Aptamer Inhibits Neointimal Formation

Lopez, 2006, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data, Lancet, 367, 1747, 10.1016/S0140-6736(06)68770-9 Heidenreich, 2011, Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association, Circulation, 123, 933, 10.1161/CIR.0b013e31820a55f5 Sollott, 1995, Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat, J Clin Invest, 95, 1869, 10.1172/JCI117867 Axel, 1997, Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery, Circulation, 96, 636, 10.1161/01.CIR.96.2.636 Fattori, 2003, Drug-eluting stents in vascular intervention, Lancet, 361, 247, 10.1016/S0140-6736(03)12275-1 Curcio, 2011, Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy, Circ J, 75, 1287, 10.1253/circj.CJ-11-0366 Centemero, 2012, Stent thrombosis: an overview, Expert Rev Cardiovasc Ther, 10, 599, 10.1586/erc.12.38 Kedia, 2007, Stent thrombosis with drug-eluting stents: a re-examination of the evidence, Catheter Cardiovasc Interv, 69, 782, 10.1002/ccd.21061 Garg, 2013, New concepts in the design of drug-eluting coronary stents, Nat Rev Cardiol, 10, 248, 10.1038/nrcardio.2013.13 Corti, 2012, Long-term patient benefit with biodegradable polymer biolimus eluting stent, Minerva Cardioangiol, 60, 629 Lupi, 2014, Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients, Eur J Prev Cardiol, 21, 411, 10.1177/2047487312467745 Kaul, 2015, Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes, N Engl J Med, 373, 1709, 10.1056/NEJMoa1510188 Tang, 2014, Smooth muscle-specific drug targets for next-generation drug-eluting stent, Expert Rev Cardiovasc Ther, 12, 21, 10.1586/14779072.2014.866518 Thiel, 2012, Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection, PLoS One, 7, e43836, 10.1371/journal.pone.0043836 Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 Thiel, 2009, Therapeutic applications of DNA and RNA aptamers, Oligonucleotides, 19, 209, 10.1089/oli.2009.0199 Keefe, 2010, Aptamers as therapeutics, Nat Rev Drug Discov, 9, 537, 10.1038/nrd3141 Sundaram, 2013, Therapeutic RNA aptamers in clinical trials, Eur J Pharm Sci, 48, 259, 10.1016/j.ejps.2012.10.014 Sundaram, 2013, Therapeutic RNA aptamers in clinical trials, Eur J Pharm Sci, 48, 259, 10.1016/j.ejps.2012.10.014 Esposito, 2011, A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death, PLoS One, 6, e24071, 10.1371/journal.pone.0024071 Povsic, 2013, A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial, Eur Heart J, 34, 2481, 10.1093/eurheartj/ehs232 Chan, 2008, A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor, J Thromb Haemost, 6, 789, 10.1111/j.1538-7836.2008.02932.x Jawien, 1992, Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty, J Clin Invest, 89, 507, 10.1172/JCI115613 Kumar, 1997, Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow, Arterioscler Thromb Vasc Biol, 17, 2238, 10.1161/01.ATV.17.10.2238 Oshiro, 2014, Pluronics f-127/l-81 binary hydrogels as drug-delivery systems: influence of physicochemical aspects on release kinetics and cytotoxicity, Langmuir, 30, 13689, 10.1021/la503021c Cheng, 2014, Thrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Akt-dependent NF-κB/p300 activation, Clin Sci (Lond), 127, 171, 10.1042/CS20130676 Lee, 2007, TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells, Am J Physiol Lung Cell Mol Physiol, 292, L799, 10.1152/ajplung.00311.2006 Lok, 2002, Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides, Biochemistry, 41, 3457, 10.1021/bi0115075 Zhang, 2004, Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways, Mol Cancer Ther, 3, 187, 10.1158/1535-7163.187.3.2 Tarner, 2004, Targeted gene therapy: frontiers in the development of ‘smart drugs', Trends Biotechnol, 22, 304, 10.1016/j.tibtech.2004.04.001 Hart, 1999, PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon, Circulation, 99, 564, 10.1161/01.CIR.99.4.564 Sirois, 1997, Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening, Circulation, 95, 669, 10.1161/01.CIR.95.3.669 Caglayan, 2011, Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo, J Am Coll Cardiol, 57, 2527, 10.1016/j.jacc.2011.02.037 Koyama, 1994, Different functions of the platelet-derived growth factor-alpha and -beta receptors for the migration and proliferation of cultured baboon smooth muscle cells, Circ Res, 75, 682, 10.1161/01.RES.75.4.682 Karvinen, 2009, PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries, Eur J Clin Invest, 39, 320, 10.1111/j.1365-2362.2009.02095.x Rubin, 1988, Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions, Lancet, 1, 1353, 10.1016/S0140-6736(88)92177-0 Majesky, 1990, PDGF ligand and receptor gene expression during repair of arterial injury, J Cell Biol, 111, 2149, 10.1083/jcb.111.5.2149 Tanizawa, 1996, Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study, Heart, 75, 549, 10.1136/hrt.75.6.549 Ross, 1986, The biology of platelet-derived growth factor, Cell, 46, 155, 10.1016/0092-8674(86)90733-6 Green, 1996, Inhibitory DNA ligands to platelet-derived growth factor B-chain, Biochemistry, 35, 14413, 10.1021/bi961544+ Leppänen, 2000, Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model, Arterioscler Thromb Vasc Biol, 20, E89, 10.1161/01.ATV.20.11.e89 Cerchia, 2009, Cell-specific aptamers for targeted therapies, Methods Mol Biol, 535, 59, 10.1007/978-1-59745-557-2_5 Ray, 2013, Application of aptamers for targeted therapeutics, Arch Immunol Ther Exp (Warsz), 61, 255, 10.1007/s00005-013-0227-0 McNamara 2nd, 2006, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras, Nat Biotechnol, 24, 1005, 10.1038/nbt1223 Dassie, 2009, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors, Nat Biotechnol, 27, 839, 10.1038/nbt.1560 Thiel, 2012, Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers, Nucleic Acids Res, 40, 6319, 10.1093/nar/gks294 Dassie, 2014, Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen, Mol Ther, 22, 1910, 10.1038/mt.2014.117